Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × adavosertib × Genitourinary × Clear all

Phase

Phase 2 2 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 6 Head & Neck 3 Gynecologic 3 Gastrointestinal 3 CNS 3 Thoracic 2 Other hematologic neoplasm 2 Tumor-Agnostic 1 Sarcoma 1 Myeloid 1 Genitourinary 1 Breast 1

Conditions

Muscle Invasive Bladder Cancer 1

Interventions

pembrolizumab 83 Nivolumab 56 Docetaxel 51 Cyclophosphamide 45 enzalutamide 38 Magnetic Resonance Spectroscopy 32 Ipilimumab 30 Gemcitabine 27 fludarabine 26 Prednisone 25 Everolimus 25 Abiraterone Acetate 25 Paclitaxel 23 Radiotherapy 22 Cisplatin 22 cabozantinib 20 Sunitinib 20 Specimen Handling 19 Carboplatin 19 atezolizumab 18 Radiosurgery 18 pazopanib 17 Sorafenib 17 Bevacizumab 17 bicalutamide 15 Biopsy 15 apalutamide 14 temsirolimus 13 darolutamide 13 abiraterone 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02546661 2025-12-29

BISCAY

AstraZeneca

Phase 1 Active not recruiting

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡